Fig. 1.
Shorter PBL TL may be coupled with enhanced sensitivity to OvC therapy. Patients responding to treatment (>12 months, n = 93) have shorter telomeres than those therapy-resistant (1–6 months, n = 46, P = 0.037).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.